Pharmacyclics Scores on Non-Hodgkins Lymphoma Data (PCYC)
Pharmacyclics Inc. (NASDAQ: PCYC) is seeing shares surge today after it said that its Phase 1/2 trial of motexafin gadolinium plus antibody targeted radiation therapy demonstrated a high complete...
View ArticleWeekend of Cancer and Ocology Data at AACR; semi-preview for ASCO (ALTH,...
This weekend will kick off a rather important oncology meeting, and it has a chance of setting the expectations for the highly anticipated ACSO (American Society of Clinical Oncology) annual meeting...
View ArticlePharmacyclics (PCYC) Rights Offering Oversubcribed
Pharmacyclics (PCYC) share are up 10% to $1.49 on news that its right offering is oversubscribed. PCYC said the preliminary results of its rights offering to purchase up to 22,500,000 shares of the...
View ArticleIs Allos Really a Buyout Candidate? (ALTH, VPHM, GERN, PCYC)
What is the oldest trick in the book when you need a share price up after it challenges 52-week lows? Float a a takeover rumor… Allos Therapeutics, Inc. (NASDAQ: ALTH) is up big on more than...
View Article
